This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Males are more often affected than females. The risk of death with proper treatment is about 5% while without it is around 75%. While cases that appear similar to MH have been documented since the early 20th century, the condition was only formally recognized in 1960.
== History == SOLAR began in 1975 as Soul Train Records, founded by Dick Griffey and Soul Train creator Don Cornelius. The first act they signed was an R&B vocal quartet they named The Soul Train Gang (Gerald Brown, Terry Brown, Judy Jones, Patricia Williamson, and later Denise Smith), who performed one of Soul Train's many themes, "Soul Train '75". Their first album was entitled Don Cornelius Presents The Soul Train Gang. In 1976, their second album, The Soul Train Gang, produced by Philly's Norman Harris, was released. The Gang broke up in 1977. That same year, singer/drummer Arnie Oliver, aka Ahaguna G. Sun, and singer/guitarist Werner "Bear" Schuchner formed Sunbear, a little-known soul/funk vocal duo that recorded in Los Angeles in 1977. Earth, Wind & Fire was a heavy influence on Sunbear, and there were also hints of Tower of Power and El Chicano in their sound. In 1977, Sunbear recorded its self-titled debut album for Don Cornelius and Dick Griffey's Soul Train Records, which evolved into Solar Records after Cornelius' departure in 1978. Sunbear broke up without ever recording a second album, and Oliver and Schuchner both went on to pursue other activities in the R&B world. Oliver became a member of Frankie Beverly's Maze, while Schuchner played guitar on albums by the Whispers, the Soul Train Gang, High Inergy, and others. In 1980, the Whispers recorded Sunbear's ballad "Fantasy" for their hit album Imagination. Griffey formed a collective called Shalamar, using a host of session singers to record "Uptown Festival," a disco-length medley of early Motown hits.
Quantum dots are usually coated with organic capping ligands (typically with long hydrocarbon chains, such as oleic acid) to control growth, prevent aggregation, and to promote dispersion in solution. However, these organic coatings can lead to non-radiative recombination after photogeneration, meaning the generated charge carriers can be dissipated without photon emission (e.g. via phonons or trapping in defect states), which reduces fluorescent quantum yield, or the conversion efficiency of absorbed photons into emitted fluorescence. To combat this, a semiconductor layer can be grown surrounding the quantum dot core. Depending on the bandgaps of the core and shell materials, the fluorescent properties of the nanocrystals can be tuned. Furthermore, adjusting the thicknesses of each of the layers and overall size of the quantum dots can affect the photoluminescent emission wavelength — the quantum confinement effect tends to blueshift the emission spectra as the quantum dot decreases in size. There are 4 major categories of quantum dot heterostructures: type I, inverse type I, type II, and inverse type II. Type I quantum dots are composed of a semiconductor core encapsulated in a second semiconductor material with a larger bandgap, which can passivate non-radiative recombination sites at the surface of the quantum dots and improve quantum yield. Inverse type I quantum dots have a semiconductor layer with a smaller bandgap which leads to delocalized charge carriers in the shell.
On 23 July 1952, a law combined the GDR's municipal districts (Kreise) into 14 regional districts (Bezirke), and subsequently, on 25 July 1952, the state governments transferred their administrative tasks to the new regional districts. With this law, the Länder were in effect dissolved, and the GDR had become a highly centralized state. While they formally remained in existence, they no longer had any political or administrative functions. The Bezirke were drawn without regard to the borders of the Länder and each named after their capitals, from north to south: Rostock, Neubrandenburg, Schwerin, Potsdam, Frankfurt (Oder), Magdeburg, Cottbus, Halle, Leipzig, Erfurt, Dresden, Karl-Marx-Stadt (named Chemnitz until 1953), Gera and Suhl. The Länderkammer also remained in existence and its members were elected in 1954 by combined sessions of the Bezirkstage (district assemblies) in each Land and in 1958 directly by the Bezirkstage. However, on 8 December 1958, the Länderkammer formally dissolved itself with no objections being raised. The Länder continued to exist de jure up until the entry into force of the 1968 Constitution, which formalized their abolition. Due to its special status, East Berlin was originally not counted as a Bezirk. In 1961, after the construction of the Berlin Wall, East Berlin came to be recognised in GDR administration as a 15th district, though it retained a special status until the adoption of the 1968 Constitution formally designated it as Bezirk Berlin.
Sources: en.wikipedia.org
Following diagnosis, the extent of the disease should be established regarding the heart, the lungs, and the muscles/bones (musculoskeletal). Metabolic functions should also be assessed, as lipodystrophy can co-occur with EDMD, by measuring levels of sugar, cholesterol, and triglycerides in the blood. Tests useful for heart evaluation include electrocardiography (EKG), echocardiography (echo), cardiac MRI, and electrophysiology studies. Musculoskeletal function can be assessed by a physical therapist or orthopedist. Regardless of the extent of the disease, cardiac and respiratory complications should be monitored. EKG, holter, and echo are recommended yearly, and additional tests can be indicated depending on heart involvement. Pulmonary function tests (PFTs) are recommended every 2–3 years, or yearly in those with respiratory involvement. Although the root cause of EDMD is not currently treatable, its manifestations and complications can be treated. Heart involvement can be addressed with medications (antiarrhythmics, beta-blockers, and ACE inhibitors), pacemakers, defibrillators, and sometimes heart transplantation. Affecting breathing can be addressed with physical therapy and, later in the disease, mechanical ventilation. Contractures and scoliosis can be addressed with orthopedic surgery. Mobility can be improved with physical therapy, occupational therapy, and mechanical aids (canes, orthoses, wheelchairs).
the theoretical predictions align with experimental results. This relation can thus be used to analyse the environment of the nanoparticle, i.e. the interfacial layer, by measuring the wavelength of the plasmon resonance.
Francis Harry Compton Crick (8 June 1916 – 28 July 2004) was an English molecular biologist, biophysicist, and neuroscientist. He, James Watson, Rosalind Franklin, and Maurice Wilkins played crucial roles in deciphering the helical structure of the DNA molecule. Crick and Watson's paper in Nature in 1953 laid the groundwork for understanding DNA structure and functions. Together with Maurice Wilkins, they were jointly awarded the 1962 Nobel Prize in Physiology or Medicine "for their discoveries concerning the molecular structure of nucleic acids and its significance for information transfer in living material". Crick was an important theoretical molecular biologist and played a crucial role in research related to revealing the helical structure of DNA. He is widely known for the use of the term "central dogma" to summarise the idea that once information is transferred from nucleic acids (DNA or RNA) to proteins, it cannot flow back to nucleic acids. In other words, the final step in the flow of information from nucleic acids to proteins is irreversible. During the remainder of his career, Crick held the post of J.W. Kieckhefer Distinguished Research Professor at the Salk Institute for Biological Studies in La Jolla, California. His later research centred on theoretical neurobiology and attempts to advance the scientific study of human consciousness. Crick remained in this post until his death in 2004; "he was editing a manuscript on his death bed, a scientist until the bitter end" according to Christof Koch.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.